Wegovy or Ozempic
No mentions found
This entity hasn't been tracked yet, or Iris is still building its knowledge base.
Related Articles from SNS
Scientists discover why Ozempic and Wegovy weight loss eventually plateaus
New NIH research reveals that semaglutide sparks different responses inside appetite-controlling brain cells, offering fresh insight into why GLP-1 weight-loss drugs don’t work the same for everyone. Scientists also found a possible way to extend the drugs’ effects, potentially helping patients push past weight-loss plateaus.
Ozempic and similar weight-loss drugs linked to 30% lower breast cancer risk
Ozempic and similar weight-loss drugs linked to 30% lower breast cancer risk Popular GLP-1 weight-loss drugs may have an unexpected bonus: a significantly lower risk of breast cancer. - Date: - June 6, 2026 - Source: - University of Pennsylvania School of Medicine - Summary: - A large study found that women taking GLP-1 drugs, the medication class behind Ozempic, Wegovy, Mounjaro, and Zepbound, were about 30% less likely to develop breast cancer.
Weight loss jab users warned not to ignore 1 symptom affecting the eyes
Weight loss jab users warned not to ignore 1 symptom affecting the eyes Health officials have issued a warning to weight loss jab users after a rare eye condition was linked to a popular medication used by thousands Millions of people use weight loss and diabetes jabs every year, but health officials are warning patients to be alert to one potentially serious symptom that could affect their eyesight. The alert concerns medicines containing semaglutide, including Wegovy, Ozempic and Rybelsus....
Noom Promo Codes: 50% Off Best Deals & Free Trials for June 2026
Founded in 2008, Noom was launched as a human-to-human weight loss coaching service, which paired psychology-based methods with fitness and food tracking to help its users reach their weight goals. Since the rise of GLP-1 medications, Noom has also introduced a model that helps GLP-1 users taking WeGovy, Ozempic, Zepbound, or similar medications create sustainable lifestyle changes and healthy habits. It has also introduced the option for AI coaching.
GLP-1 drugs, including Ozempic, may have a beneficial effect across many types of cancer
GLP-1 drugs, including Ozempic, may have a beneficial effect across many types of cancer More than two dozen studies suggest the treatments are linked to lower cancer risk, reduced metastasis and improved survival, though researchers say trials are needed to confirm any anti-cancer benefit. A growing body of evidence suggests that popular GLP-1 drugs, widely used for weight loss and diabetes, can provide protection against many types of cancer. More than two dozen studies presented over the...
Ozempic-like drugs may improve kidney disease outcomes: study
Semaglutide and Ozempic-like drugs may improve kidney disease outcomes Wed 3 Jun 2026 at 5:00am In short: New research shows people with type 2 diabetes and chronic kidney disease who took semaglutide (commonly sold as Ozempic) once a week had improved kidney outcomes, even if they have heart disease or heart failure. This builds on previous research which found the drug had "consistent benefits" preventing heart attacks, strokes, and death due to cardiovascular causes in those with chronic...
Life-changing medicine or beauty hack? How Ozempic came to be seen as both, and why that's risky
Life-changing medicine or beauty hack? How Ozempic came to be seen as both, and why that's risky The same drug that is helping patients manage diabetes and reduce their risk of serious complications from chronic conditions is also being discussed as a beauty hack by people hoping to lose a few kilograms. Experts say more education and awareness are needed.
Scientists discover why ozempic may not work for some people
Scientists discover why ozempic may not work for some people A hidden genetic quirk may be making some people surprisingly resistant to the benefits of blockbuster GLP-1 diabetes drugs. - Date: - June 5, 2026 - Source: - Stanford Medicine - Summary: - Scientists have identified genetic variants that may make some people less responsive to GLP-1 drugs used to treat Type 2 diabetes.
Weekly diabetes jab shown to reduce blood-sugar levels and body weight
Experts say results from trial of new triple hormone drug for type 2 diabetes are striking but further tests neededA new triple-action weekly jab for type 2 diabetes could significantly reduce blood sugar and body weight, according to phase 3 trial results. Patients in the trial receiving weekly retatrutide injections for 40 weeks lost more than four times as much weight as those on placebo, while the average drop in long-term blood sugar (HbA1c) was more than twice that of the placebo. The...
Weekly diabetes jab shown to reduce blood-sugar levels and body weight
Experts say results from trial of new triple hormone drug for type 2 diabetes are striking but further tests neededA new triple-action weekly jab for type 2 diabetes could significantly reduce blood sugar and body weight, according to phase 3 trial results. Patients in the trial receiving weekly retatrutide injections for 40 weeks lost more than four times as much weight as those on placebo, while the average drop in long-term blood sugar (HbA1c) was more than twice that of the placebo. The...